MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.695
+0.045
+2.73%
After Hours: 1.636 -0.059 -3.49% 16:17 09/20 EDT
OPEN
1.660
PREV CLOSE
1.650
HIGH
1.714
LOW
1.650
VOLUME
121.99K
TURNOVER
--
52 WEEK HIGH
10.96
52 WEEK LOW
0.8500
MARKET CAP
43.64M
P/E (TTM)
-0.4736
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OTLK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OTLK News

  • 71 Biggest Movers From Yesterday
  • Benzinga.09/12 09:33
  • CBL, GME, SATS, and ZS among midday movers
  • Seeking Alpha - Article.09/11 16:39
  • 48 Stocks Moving In Wednesday's Mid-Day Session
  • Benzinga.09/11 16:27
  • Benzinga's Top Upgrades, Downgrades For September 11, 2019
  • Benzinga.09/11 14:31

More

Industry

Biotechnology & Medical Research
+0.62%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Name
Price
%Change

About OTLK

Outlook Therapeutics, Inc., formerly Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.
More

Webull offers Outlook Therapeutics Inc (OTLK) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.